Voorbeelden van EU gefinancieerd onderzoek naar neuroziektes zoals Alzheimer (en) - Hoofdinhoud

MEMO/09/347

Brussels, 22 July 2009

Examples of EU-funded research on neurodegenerative diseases

This background note provides some examples of research on neurodegenerative diseases supported through the EU's Research Framework Programme.

• 1) 

  Research on Alzheimer's disease

Alzheimer's disease is the most common cause of dementia in the EU (between 50 and 70% of all dementia). Dementia is a decline in mental ability that usually progresses slowly, in which memory, thinking, and judgement are impaired and personality may deteriorate. It usually develops slowly, and affects mainly people aged over 60. It is one of the most important causes of disability in the elderly.

PROMEMORIA

The PROMEMORIA project investigates the function of small molecules that participate in the process of memory formation by helping neurons interact with each other. The ultimate goal is to develop compounds with a beneficial effect on diseases involving cognitive impairment, including Alzheimer's.

Coordinator

Prof. Elisabeth Bock

University of Copenhagen

Institute of Molecular Pathology

Copenhagen, Denmark

E-mail: bock@plab.ku.dk

EC contribution: €9 700 000

Starting date: 01/04/2005

Duration: 48 months

Project web-site: http://plab.ku.dk/promemoria/

Partners:

Participant name	Country
University of Copenhagen	Denmark
The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elisabeth near Dublin	Ireland
Institute of Neurology – University College London	United Kingdom
Centre National de la Recherche Scientifique	France
Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen	Germany
University of Geneva, Medical Faculty	Switzerland
The OPEN UNIVERSITY	UK
Instituto Cajal, Consejo, Superior de Investigaciones Cientificas	Spain
Medizinische Hochschule Hannover	Germany
International Institute of Molecular and Cell Biology	Poland
Lund University	Sweden
Ecole Polytechnique Federale de Lausanne	Switzerland
University of Haifa	Israel
ENKAM Pharmaceuticals A/S	Denmark
NeuroPharma S.A.U.	Spain
Schafer-N	Denmark
University of Tartu	Estonia

ADIT

The ADIT project wants to identify new molecules capable of reducing the mortality of neurons (the neuroprotectants) in Alzheimer's disease. The ultimate goal is to put the identified molecules in an efficient drug discovery pipeline and bring two drug candidates to the clinic.

Coordinator :

Dr. Georg C. Terstappen

Siena Biotech S.p.A.

Discovery Research Division

Siena, Italy

E-mail: gterstappen@sienabiotech.com

EC contribution: € 7 485 490

Starting date: 01/06/2005

Duration: 60 months

Project web-site: http://www.aditproject.org/

Partners:

Figures and graphics available in PDF and WORD PROCESSED

EDAR

The objective of the EDAR study is to develop ultra-sensitive tests to measure beta amyloid oligomers – the molecules believed to be responsible for Alzheimer's disease – in Alzheimer's patients . The ultimate goal is to obtain a test that not only provides an early diagnosis of Alzheimer's, but can also assess if a patient is responding properly to a treatment or not.

Coordinator

Dr Pieter Jelle Visser

Vrije Universiteit Medisch Centrum

Alzheimer Centre Department of Neurology

Amsterdam, The Netherlands

E-mail: pj.visser@vumc.nl

EC contributi on: € 621 002

Starting date: 01/01/2007

Duration: 36 months

Project web-site: http://www.edarstudy.eu/

Partners:

Participant name	Country
Vereniging voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek en P atientenzorg	The Netherlands
Chimera Biotech GmbH	Germany
Hycult biotechnology b.v	The Netherlands
Academisch Medisch Centrum bij de Universiteit van Amsterdam	The Netherlands
Karolinska Institutet	Sweden
Aristotle University of Thessaloniki	Greece
Katholieke Universiteit Leuven	Belgium
Region Hovedstaden	Denmark
Ludwig Maximilian University of Munich	Germany
University of Maastricht	The Netherlands
Abbott GmbH& Co.KG	Germany

• 2) 

  Research on Parkinson's disease

Parkinson's disease is characterized by problems with body movements (tremor at rest, slowing of voluntary movements, muscle weakness etc). It is the second most prevalent of all neurodegenerative diseases after Alzheimer's.

NEuroStemCell

The NEuroStemCell consortium aims at paving the way for successful clinical trials of stem cell therapy for Parkinson's and Huntington's disease. Stem cells have the capacity, when cultured properly, to acquire the same properties as other cell types, including neurones. The goal of the project is to compare different stem cell sources and see which one is the most suitable to replace the neurones that are lost in these two diseases.

Coordinator

Prof. Elena Cattaneo

University of Milano

Department of Pharmacological Sciences and Centre for Stem

Cell Research

Milan, Italy

E-mail: elena.cattaneo@unimi.it

EC contribution: € 11 900 000

Starting date: 01/12/2008

Duration: 48 months

Project web-site: http://www.neurostemcell.org/

Partners:

Participant name	Country
UNIVERSITA DEGLI STUDI DI MILANO	Italy
LUNDS UNIVERSITET	Sweden
UNIVERSITAETSKLINIKUM BONN	Germany
KAROLINSKA INSTITUTET	Sweden
CARDIFF UNIVERSITY	United Kingdom
COMMISSARIAT ENERGIE ATOMIQUE CEA	France
UNIVERSITY OF CAMBRIDGE	United Kingdom
INSERM	France
IMPERIAL COLLEGE	United Kingdom
BIOREP SRL	Italy
NsGene A/S	Denmark
Stem Cell Sciences PLC	United Kingdom

INDABIP

The INDABIP project wants to identify small molecules (biomarkers) that would permit the early diagnosis of Parkinson’s disease and that could therefore be used to develop better diagnostic tests. The second aim of the INDABIP project is to identify molecules playing a key role in the disease and to evaluate their potential as drug targets.

Coordinator

Tamara Maes

C.S.O. Oryzon genomics

Barcelona, Spain

E-mail: tmaes@oryzon.com

EC contribution: € 1 600 000

Starting date: 01/12/2006

Duration: 36 months

Project web-site: http://www.indabip.eu/

Partners:

Participant name	Country
ORYZON GENOMICS	Spain
Institut d'Investigació Biomèdica de Bellvitge	Spain
GENFIT SA	France
Ludwig-Maximillians-University Munich	Germany
University of Kuopio	Finland
Université de Lille 2	France

• 3) 

  Research on rare neurodegenerative diseases

Rare neurodegenerative diseases are diseases whose prevalence is less than 1 in 2000. They include amyotrophic lateral sclerosis and other motor neuron diseases, Huntington's disease and other degenerative diseases with chorea (abnormal involuntary movement disorder), ataxias (lack of coordination of muscles movements), prion diseases (for example Creutzfeldt-Jakob Disease) , iron and copper disorders and mitochondrial diseases.

EUROSCA

The EUROSCA network aims at developing a treatment for patients suffering from spinocerebellar ataxias (SCA). The project will develop international standards for the clinical evaluation of the disease in the form of a Core Assessment Programme for Interventional Therapies of SCA (CAPIT-SCA). It will also establish the European SCA Registry (EUROSCA-R), the world’s largest collection of information on SCA patients. This it will ensure standardised data acquisition and facilitate continuous enrolment of SCA patients throughout Europe.

Coordinator

Prof. Olaf Riess

Eberhard Karls-Universitaet Tuebingen

Department of Medical Genetics

Tuebingen, Germany

E-mail: olaf.riess@med.uni-tuebingen.de

EC contribution: €9 450 000

Starting date: 01/01/2004

Duration: 60 months

Project web-site: http://www.eurosca.org/

Project video: http://www.youris.com/Health/Genetics/Genes_out_of_Balance.kl

Partners:

Participant name	Country
Olaf Riess, UKT Tübingen	Germany
Nicholas William Wood, IoN London	United Kingdom
Thomas Klockgether, Neurology Bonn	Germany
Alexis Brice, INSERM Paris	France
Bernard Sablonniere, INSERM Lille	France
Stefano DiDonato, INMB Milan	Italy
David Rubinsztein, CMRC Cambridge	United Kingdom
Massimo Pandolfo, ULB Brussels	Belgium
Bart van de Warrenburg, Nijmegen	The Netherlands
Jacek Zaremba, DG-IPN Warsaw	Poland
Bela Melegh, Uiversity of Pecs	Hungary
José Berciano, UHMV Santander	Spain
Sandra Szymanski, Neurology Bochum	Germany
Georg Auburger, Neurogenetics Frankfurt	Germany
Christine Zühlke, Human Genetics Lübeck	Germany
Hervé Tricoire, DCF CNRS Paris	France
Erich E. Wanker, MDC Berlin	Germany
Yvon Trottier IGBMC Illkirch	France
Neil Quentin McDonald BC London	United Kingdom
Annalisa Pastore NIMR London	United Kingdom
Jörg B. Schulz HM Göttingen	Germany
Antoni Matilla IGTP Badalona	Spain

TAMAHUD

This project aims at identifying novel molecules contributing to the development of Huntington’s disease in order to develop efficient drugs against the disease and novel biomarkers for early diagnosis. Biomarkers are molecules that show the presence of the disease.

Coordinator

Dr Andrea Caricasole

Siena Biotech SpA

Siena, Italy

E-mail: acaricasole@sienabiotech.com

EC contribution: € 3 000 000

Starting date: 01/01/2007

Duration: 42 months

Project web-site: http://www.tamahud.eu/home.jsp

Partners:

Participant name	Country
Sienabiotech SpA	Italy
University of Cambridge	United Kingdom
TCP Innovations	United Kingdom
Alma Bioinformatics S.L	Spain
EMBL Heidelberg	Germany
Total Scientific	United Kingdom

• 4) 

  Networking activities

The European Community also funds transnational networks to overcome fragmentation of research in a specific area.

NeuroNE

The NeuroNE consortium studies the basic mechanisms of disease in order to develop novel therapeutic approaches to neurodegenerative diseases and spinal cord injury. NeuroNE brings together investigators from different backgrounds (basic scientists, active clinicians and biomedical companies) to work at multiple levels: basic research, preclinical research, and clinical studies. The network mostly focuses on Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).

Coordinator

Prof. James Fawcett

University of Cambridge

Cambridge Centre for Brain Repair

Cambridge, United Kingdom

E-mail: jf108@cam.ac.uk

EC contribution: €8 300 000

Starting date: 01/01/2005

Duration: 54 months Project web-site: http://neurone.nuxit.net/

Partners:

Participant name	Country
Cambridge University	United Kingdom
Ecole Polytechnique Fédérale de Lausann e	Switzerland
Universität Heildelberg	Germany
Universität Gottingen	Germany
Lund University	Sweden
Friedrich Miescher Institut	Switzerland
Università di Milano	Italy
Technion-Israel Institute of Technology	Israel
Commissariat à l'Energie Atomique	France
Institut National de la Santé et de la Recherche Médicale	France
Ludwig-Maximilians-Universitaet Muenchen	Germany
Karolinska Institute	Sweden
Université de Genève	Switzerland
Max-Planck Institute	Germany
Universitätsklinikum Ulm	Germany
Kings College London	United Kingdom
Flanders Interuniversity Institute for Biotechnology VZW	Belgium
Consejo Superior de Investigaciones Científicas	Spain
University of Zurich	Switzerland
University of Turin	Italy
INSERM Transfert	France
Trophos	France
Xantos GmbH	Germany
Genetrix SL	Spain
Pharmaxon	France
Miltenyi Biotec	Germany
Centre National de la Recherche Scientifique	France
Istituto Veneto di Medicina Molecolare	Italy
D-PHARM Ltd	Israel
The Babraham Institute	United Kingdom
Medical Research Centre	United Kingdom

BrainNet Europe II

BrainNet Europe is a "Network of Excellence" that collects human post-mortem brain tissue (i.e brain banking). Collecting such tissue is essential as this tissue can then used by researchers to carry out research on diseases such as Alzheimer's and Parkinson's. Expected results include the development of guidelines describing the best practice for brain banking, providing training in brain banking, and reaching out to neuroscience centres worldwide to promote future expertise in biobanking and central nervous system research.

Coordinator:

Prof. Hans Kretzschmar

Ludwig Maximilians Universitaet Muenchen

Institute of Neuropathology and Prion Research

Munich, Germany

E-mail: Hans-Kretzschmar@med.uni-muenchen.de

EC contribution: €7 740 000

Starting date: 01/07/2004

Duration: 66 months

Project web-site: www.brainnet-europe.org

Partners:

Figures and graphics available in PDF and WORD PROCESSED

Figures and graphics available in PDF and WORD PROCESSED

• 5) 

  Public and private Partnerships

The European Commission also encourages public and private partnerships in research. Launched in 2007, the Innovative Medicines Initiative (IMI) is an example of such partnerships: it involves both the European Community and the pharmaceutical industry (EFPIA - European Federation of Pharmaceutical Industries and Associations)

One of the projects selected within IMI's first call for proposals is PharmaCOG which aims at predicting cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development.

The PharmaCOG project, with a co-founding of € 9M by the European Community and € 13M by the EFPIA partners, is one of the most ambitious projects tackling Alzheimer's disease ever funded at European level.

PharmaCOG offers a complete innovative approach to Alzheimer's treatment drug discovery. Indeed, the major obstacle to new drugs development is the promising pharmaceutical molecules failure rate through the medicines' development process, with regard to criteria such as toxicity and efficiency. PharmaCOG will define more precisely the potential of a drug candidate, reduce its development time and thus accelerate the marketing of promising new drugs in the treatment of Alzheimer’s disease. Through the joint effort of 30 European partners (within 9 European countries) from 12 fundamental and clinical public research institutions, 5 innovative SMEs, 12 Big Pharma companies and 1 patient’s association, PharmaCOG will validate the tools needed to streamline and accelerate the discovery of drugs effective in treating Alzheimer's disease.

Coordinator:

Glaxosmithkline Research and Development Ltd

Managing entity: Université de la Méditerranée – Aix-Marseille II

EC contribution: €9 000 000

EFPIA "in kind" contribution: € 13 000 000

Duration: 60 months

See also IP/09/1171 , MEMO/09/345 and MEMO/09/346